NEWS & MEDIA

First Patient Treated in Clinical Study of OsteoActivator-P Membranes for Accelerated Alveolar Ridge Preservation

Osteo-Pharma today announced that the first patient has been treated for the clinical trial ‘OsteoActivator-P for accelerated localized alveolar ridge preservation’. The study is a randomized prospective clinical trial, comparing OsteoActivator-P coated membranes vs Collagen Membrane-P uncoated for accelerated localized alveolar ridge preservation and will investigate the efficacy and safety of OsteoActivator-P. The study is expected to enroll a total of 16 patients at 2 clinical centers in The Netherlands.

read more

About Osteo-Pharma

Osteo-Pharma is a Life Sciences company focused on the development of local treatments to improve the healing of bone fracture and defects. It’s proprietary OsteoActivator platform is used to develop biodegradable films, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in mid-stage pre-clinical development for various projects and will start its first dental clinical trial in mid-2021.